Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine

WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine.  The following distinguished investigators join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School of Medicine Melvin and Bren Simon Cancer Center), and Dr. Hope S. Rugo, MD (University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center) on the SAB:

Dr. Keith L. Knutson. PhD
Associate Professor, Department of Immunology
Mayo Clinic

Dr. Knutson's current interests and research focus on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials.  His laboratory research on cancer vaccines focuses on augmenting CD4 helper T cell immunity using peptide epitopes.  These vaccine strategies are aimed at preventing patients from relapsing after optimal conventional therapies.  Adoptive T cell therapy is also being examined, a strategy that involves infusing high numbers of T cells into patients with active bulky malignancy.

In addition to his research, Dr. Knutson participates in and chairs several study sections; is Director of the Mayo Clinic Cancer Center Immunology and Immunotherapy Program; Co-director, Mayo Clinic Immune Monitoring Core; and Director, Ovarian Cancer Immunotherapy Program at Mayo Clinic.

Dr. Knutson received his PhD from the University of Georgia in Physiology and Pharmacology in 1995 and completed two post-doctoral fellowships in immunology: one at the University of British Columbia; and the other at the University of Washington.  He was a 2004 recipient of a Howard Temin Award from the National Cancer Institute.

Dr. James J. Mule
Moffitt Cancer Center

Dr. Mule is the Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.

He serves on the Board of Directors of Medicine in Need, Cambridge, MA and is a member of the Scientific and Medical Advisory Board of Aura Biosciences; selected as 2011 and 2010 Technology Pioneers, respectively, by the World Economic Forum, Davos.  Dr. Mule remains a long-standing special government employee to the FDA and the NCI.  He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA.

Dr. Mule currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director's Board of Scientific Counselors (BSC-A, clinical).  Dr. Mule has or is currently serving on the Scientific/Medical Advisory Boards of numerous privately or publicly held companies (e.g., Celgene, Genesis Biopharma), and has been or is a consultant to many others.  Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.  His clinical research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors.  Dr. Mule has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy. 

Dr. Mule received his post-graduate degrees from the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington.  He then received his  formal post-graduate training at the Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, and soon became a tenured, Senior Investigator there at the Surgery Branch.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED